Semaglutide , a GLP-1 medication has shown early cardiovascular disease but not diabetes. More researches shows it can reduce cardiovascular problems and heart attack. In the first 3 months semaglutide reduced the risk of MACE by 38% between months 3 and 6, the relative reduction in risk with semaglutide was 41%. It can reduce heart attack and other cardiovascular problems in adults.
Dr. Jorge Plutzky, lead author, Director of Preventive Cardiology, Cardiovascular Medicine: “ The result shows decreasing cardiovascular events with significantly benefits shown by first six months” The functions of body natural incretin hormones which help to reduce body sugar levels after a meal and provide a fullness signal to brain.
Data: The researcher’s looked at data from 17,064 adults from 804 sites in different countries with overweight or obesity who were enrolled and treated with weekly injections of semaglutide. The results were quite impressive in which there was a sudden decrease in cardiovascular problems after injecting semaglutide.
The drug also have some positive effects including decreasing sugar levels , blood pressure , early dietary changes and reduce inflammation. Most patients had not yet lost more weight and many were not on fully target dose. The benefits were seen in early 20 days and it reduce cardiovascular diseases up to 41% as compare to placebo.
According to doctor plutzky: “ Effects of semaglutide without significant weight loss is seen and it can reduce cardiovascular diseases up to 42%”
Semaglutide a glucagon like peptide 1 has seveal effects on body:
Reduce glucose production, improve insulin sensitivity , inflammation reduction and reduce risks of MACE ( reducing risks of adverse cardiovascular events) It also allows glucose to enter cell more efficiently , it enhances insulin sensitivity. Semaglutide also reduce fat and give feelings of hunger through which it leads to weight loss.
cientific Research: According to research 62.9% patients treated with semaglutide seen reduction in liver inflammation. It reduces cardiovascular problems by 31% in first three months and by 42% in six months.
Conclusion: We can conclude semaglutide can reduce heart problem risks, it also reduce liver inflammation, it alsi shows progession of kidney disease in people with type 2 diabetes.
